

Molecular cancer therapeutics

Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody–drug conjugate

View Publication

Details

Authors:

Shweta Singhal, Olga Vasiljeva, et al.

Title of the Article:

Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody–drug conjugate

Journal:

Molecular cancer therapeutics

Year of Publication:

2022

Pages:

1326-1-1336

Volume and Issue Number:

vol. 21, no. 8

ISSN Number:

1538-8514

DOI (Digital Object Identifier):

10.1158/1535-7163.MCT-21-0193

COBISS ID:

116988419

Researchers

Researchers

Meet our dedicated researchers behind this publication:

Olga Vasiljeva

References

References & Citations

More documentation

Related publications

Browse all publications

Communications biology

Domain sliding of two Staphylococcus aureus N-acetylglucosaminidases enables their substrate-binding prior to its catalysis

PINTAR, Sara, BORIŠEK, Jure, USENIK, Aleksandra, PERDIH, Andrej, TURK, Dušan

10.1038/s42003-020-0911-7

Clinical cancer research

Probody therapeutic design of 89Zr-CX-072 promotes accumulation in PD-L1-expressing tumors Compared to normal murine lymphoid tissue

GIESEN, Danique, BROER, Linda N., LUB-DE HOOGE, Marjolijn N., POPOVA, Irina, HOWNG, Bruce, NGUYEN, Margaret, VASILJEVA, Olga, VRIES, Elisabeth G. de, POOL, Martin

10.1158/1078-0432.CCR-19-3137

Assessing autophagy in archived tissue or how to capture autophagic flux from a tissue snapshot

HUMBERT, Magali, ŽEROVNIK

10.3390/biology9030059

Explore our collection of 200+ Premium Webflow Templates